
Peer reviewed version

Link to published version (if available):

Link to publication record in Explore Bristol Research
PDF-document

NOTICE: this is the author's version of a work that was accepted for publication in Pain. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Pain, [Volume 155(3), March 2014] DOI10.1016/j.pain.2013.12.018

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
Systemic dexmedetomidine augments inhibitory synaptic transmission in the superficial dorsal horn through activation of descending noradrenergic control: an in vivo patch-clamp analysis of analgesic mechanisms

Yusuke Funai¹,², Anthony Edward Pickering³, Daisuke Uta¹, Kiyonobu Nishikawa², Takashi Mori², Akira Asada², Keiji Imoto¹,⁴, and Hidemasa Furue¹,⁴

¹Dept Information Physiology, National Institutes for Physiological Sciences, Okazaki 444-8787, Japan
²Dept Anesthesiology, Osaka City University Graduate School of Medicine, Osaka, 545-8586, Japan
³School of Physiology & Pharmacology, University of Bristol, Bristol BS81TD, UK
⁴Sch Life Science, The Graduate University for Advanced Studies (SOKENDAI), Okazaki 444-8787, Japan

Abstract

α₂-adrenoceptors are widely distributed throughout the central nervous system (CNS) and the systemic administration of α₂-agonists such as dexmedetomidine produces clinically useful, centrally-mediated sedation and analgesia; however, these same actions also limit the utility of these agents (ie unwanted sedative actions). Despite a wealth of data on cellular and synaptic actions of α₂-agonists in vitro, it is not known which neuronal circuits are modulated in vivo to produce the analgesic effect. To address this issue, we made in vivo recordings of membrane currents and synaptic activities in superficial spinal dorsal horn neurons and examined their responses to systemic dexmedetomidine. We found that dexmedetomidine at doses that produce analgesia (<10 μg/kg) enhanced inhibitory postsynaptic transmission within the superficial dorsal horn without altering excitatory synaptic transmission or evoking direct postsynaptic membrane currents. In contrast, higher doses of dexmedetomidine (>10 μg/kg) induced outward currents by a direct postsynaptic action. The dexmedetomidine-mediated inhibitory postsynaptic current (IPSC) facilitation was not mimicked by spinal application of dexmedetomidine and was absent in spinalized rats, suggesting it acts at a supraspinal site. Further it was inhibited by spinal application of the α₁-antagonist prazosin. In the brain stem, low doses of systemic dexmedetomidine produced an excitation of locus coeruleus neurons. These results suggest that systemic α₂-adrenoceptor stimulation may facilitate inhibitory synaptic responses in the superficial dorsal horn to produce analgesia mediated by activation of the pontospinal

Correspondence should be addressed to: Hidemasa Furue, Department of Information Physiology, National Institute for Physiological Sciences, 5-1 Higashiyma, Myodaiji, Okazaki 444-8787, Japan. furue@nips.ac.jp; Tel, +81-564-59-5887; Fax, +81-564-59-5891.

Conflict of interest statement: There are no financial or other relationships that may cause a conflict of interest.
noradrenergic inhibitory system. This novel mechanism may provide new targets for intervention perhaps allowing analgesic actions to be dissociated from excessive sedation.

1. Introduction

Clinically $\alpha_2$-adrenoceptor agonists such as dexmedetomidine are widely used as sedative agents, as adjuncts to anesthesia and have been noted to produce analgesic effects [9; 13; 38]. Dexmedetomidine is a potent analgesic but the accompanying sedation (and hypotension) produced by systemic administration has limited the widespread deployment of $\alpha_2$-agonists as analgesics and prompted investigations to separate these effects. It has been suggested that the sedative action of dexmedetomidine is primarily mediated by inhibition of locus coeruleus (LC) neurons, which has an important role in attention and arousal [2; 4; 12; 15]. Whereas there is evidence suggesting that the spinal cord is the principal site for its analgesic action [35; 61], and previous behavioral studies have shown that intrathecal or epidural dexmedetomidine is antinociceptive [3; 18]. However, there is conflicting evidence suggesting that after systemic administration it may act to produce analgesia via an action at the LC [26].

In addition to the LC and spinal cord, $\alpha_2$-adrenoceptors are widely distributed throughout the central nervous system (CNS) and mediate responses to the release of endogenous central catecholamines [24; 43]. Activation of postsynaptic $\alpha_2$-adrenoceptors produces hyperpolarization by the activation of G protein-coupled inwardly-rectifying potassium channels via $G_{i/o}$-proteins. Presynaptic $\alpha_2$-adrenoceptors reduce neurotransmitter release by inhibiting calcium influx (see review [52]). In the noradrenergic neurons of the LC, $\alpha_2$-adrenoceptors act as autoreceptors to reduce local noradrenaline release [33] and also induce postsynaptic hyperpolarization [2; 12; 15].

Within spinal nociceptive circuits, the substantia gelatinosa (SG, lamina II) neurons in the superficial dorsal horn play an important role in the transmission and modulation of nociceptive information [11; 20]. The SG receives nociceptive information via glutamatergic synapses from peripheral A$\delta$- and C- afferent fibers [22; 42; 44; 47; 63; 66]. SG neurons also receive abundant inhibitory synaptic inputs from spinal GABAergic and glycinergic interneurons [7; 41; 48; 68] and receive a dense innervation from a descending inhibitory system including noradrenergic fibers from the LC [8; 30; 50; 55]. A number of in vitro studies have shown spinal $\alpha_2$-agonists to produce both post-synaptic hyperpolarization [49] and presynaptic inhibition of excitatory transmission [37]. A recent electrophysiological study has specifically shown dexmedetomidine to have a direct inhibitory action on SG neurons in vitro [31]. It is likely that these mechanisms mediate the analgesic effects of spinaly administered $\alpha_2$-agonists, but it is not known whether the systemic administration of dexmedetomidine acts to modulate spinal nociceptive processing in a similar manner.

We have developed an in vivo patch-clamp recording technique from SG neurons in allowing the detailed analysis of synaptic responses and changes in intrinsic membrane properties [19; 22]. We used this approach to test the hypothesis that systemic dexmedetomidine, at analgesic doses, acts to inhibit SG neurons in vivo by one of the previously reported mechanisms [37; 49]. We found that low-dose dexmedetomidine (at
doses below that shown to have sedative actions) dramatically enhanced spinal inhibitory transmission (without effects on excitatory transmission or intrinsic membrane conductances) by activation of the pontospinal descending noradrenergic circuit.

2. Materials and methods

2.1 Animals

Ninety male Sprague-Dawley rats aged 5-9 weeks, weighing 150-350 g were used in this study. The animals were purchased from Japan SLC (Hamamatsu, Japan) and housed in a temperature-controlled room (21 ± 1°C) with a 12 hour light/dark cycle, and given free access to food and water. All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee of the National Institutes of Natural Sciences, and were performed in accordance with the institutional guidelines for animal experiments and were consistent with the ethical guidelines of the International Association for the Study of Pain. All efforts were made to reduce the number of animals for this study. At the end of the experiment, the animals were killed with supplemental administration of urethane (2-4 g/kg, i.p.).

2.2 Spinal nerve ligation model

Rats aged 5 weeks were used for the spinal nerve ligation model. Under sevoflurane anesthesia (3-5 %in O₂, delivered by mask) the right L5 and L6 spinal nerves were isolated and ligated tightly with 6-0 silk suture, according to the method of Chung [39]. One week after the surgery, the withdrawal threshold of the ipsilateral hind paw was assessed with von Frey filaments. Animals whose withdrawal threshold was below 8 g (6 weeks old) were used for in vivo patch-clamp recordings.

2.3 Behavioral tests

Behavioral testing was carried out in a quiet room away from the colony room in daylight and at standard temperature (24 ± 1°C). Thirteen rats aged 6 weeks were included in this protocol. The rats were allowed to acclimatise to the test location for ~1 hour before the experiment. Rats were put onto a perforated metal platform, and mechanical stimuli were delivered to the plantar surface of the hind paw using the Dynamic Plantar Aesthesiometer (37450, Ugo Basile, Comerio, Italy) positioned beneath the platform. The equipment raises a straight metal filament of diameter of 0.5 mm until it touches the plantar surface of the hindpaw and exerts an increasing upwards force (from 1 to 50 g over 20 s) until the paw is withdrawn or the preset cut-off is reached (50 g). Dexmedetomidine was administered intraperitoneally sequentially from low to high dose in the same rat. Twenty minutes after the administration of each dose, the mechanical withdrawal threshold was measured for the right paw from the average of five Aesthesiometer trials.

Six rats aged 6 weeks were used for sedation assessment. The observation chambers for sedation assessment were 20×20×14cm clear plastic cage with mesh floor. The rats were habituated to the chamber for ~1 hour before the experiment. All rats were administered 0.01, 0.1, 1, 10 and 30 μg/kg of dexmedetomidine intraperitoneally in a sequential manner. The sedation assessments were performed 20 minutes after each drug administration.
adopted the sedation rating scale of Chuck et al. [14]. The ratings were as follows: 5-awake, active: engaged in locomotion, rearing, head movements or grooming; 4-awake, inactive: eyes fully open, head up, little to no locomotion, rearing or grooming, normal posture; 3-mild sedation: eyes partly closed, head somewhat down, impaired locomotion including abnormal posture, use only some limbs, dragging and stumbling; 2-moderate sedation: head mostly or completely down, eyes partly closed, flattened posture, no spontaneous movement; 1-heavy sedation: eyes mostly closed, loss of righting reflex; 0-asleep: eyes fully closed, body relaxed, asleep.

2.4 In vivo patch-clamp recording from SG neurons

The methods used for the in vivo patch-clamp recording from the SG were similar to those described previously [19; 21; 58]. Briefly, the rats (n = 66) were anesthetized with urethane (1.2-1.5 g/kg, i.p.). Thoracolumbar laminectomy was performed at the level of T12 to L2 to expose the lumbar enlargement of the spinal cord. In the case of spinalized rats (3 rats), an additional laminectomy was made at the cervical level to allow right-sided cord hemisection to interrupt descending inhibitory pathways ipsilateral to the recording site. The rat was placed in a stereotaxic apparatus (Model ST-7, Narishige, Tokyo, Japan). After the dura mater was opened, the pia-arachnoid membrane was cut to make a window to allow the patch electrode to enter into the SG. The surface of the spinal cord was irrigated with 95 % O₂ - 5 % CO₂ equilibrated Krebs solution (in mM: 117 NaCl, 3.6 KCl, 2.5 CaCl₂, 1.2 MgCl₂, 1.2 NaH₂PO₄, 11 glucose, and 25 NaHCO₃) at a flow rate of 10-15 ml/min at 38 ± 1 °C. Patch electrodes were fabricated from thin-walled borosilicate glass capillaries using a puller (p-97, Sutter Instrument, Novato, CA), and had resistances of 8-15 MΩ when filled with either of potassium-based (in mM: 135 K-gluconate, 5 KCl, 0.5 CaCl₂, 2 MgCl₂, 5 EGTA, 5 Mg-ATP, 5 HEPES, pH 7.2 adjusted with KOH) or cesium-based (in mM: 110 Cs₂SO₄, 5 tetraethylammonium, 0.5 CaCl₂, 2 MgCl₂, 5 EGTA, 5 Mg-ATP, 5 HEPES, pH 7.2 adjusted with CsOH) intracellular solutions. The potassium- and cesium- solutions were used for recordings of outward currents and excitatory postsynaptic currents (EPSCs) at a holding potential of −70 mV and inhibitory postsynaptic currents (IPSCs) at 0 mV, respectively.

The patch electrode was advanced into the spinal cord using a micromanipulator (Model MHW-4, Narishige). Blind whole-cell recordings [67] were obtained from SG neurons at a depth of 30-200 μm from the surface [22]. The recorded currents were amplified (Axopatch 200B, Molecular Devices, Sunnyvale, CA) and digitized (Digidata 1321A, Molecular Devices) for storage/analysis on a personal computer using a data acquisition program (Clampex version 10.3, Molecular Devices). The frequencies and amplitudes of EPSCs/IPSCs were analyzed with MiniAnalysis software (Synaptosoft, Fort Lee, NJ). The total area of IPSCs over a 10 second period (before and in the presence of α₂-agonist) was measured with Clampfit software (version 10.3, Molecular Devices) reflecting the ongoing synaptic charge transfer (pC).

2.5 Extracellular recording from the LC

Eight rats aged 5-8 weeks were included in this protocol. Conventional extracellular and in vivo cell-attached patch-clamp recordings were obtained from LC neurons as described
previously [51; 59]. Under urethane anesthesia (1.2-1.5 g/kg, i.p.), rats were mechanically ventilated after tracheostomy and bilateral thoracotomy was performed to reduce the respiratory movement. The head was fixed in a stereotaxic apparatus (Model SR-5R, Narishige). The floor of the fourth ventricle was exposed through a posterior occipital craniotomy using gentle suction aspiration to remove the central portion of the cerebellum. The surface of the exposed brainstem was irrigated with Krebs solution equilibrated with 95% O\textsubscript{2} - 5% CO\textsubscript{2} at 38 ± 0.5°C at a flow rate of 5-10 ml/min. A tungsten electrode (impedance, 1 MΩ, A-M systems, Sequim, WA) electrode was placed into the LC and action potentials in LC neurons were extracellularly recorded with an AC differential amplifier (DAM 80, World Precision Instruments, Sarasota, FL). Firing rate of LC neurons was analyzed with Offline Sorter software (version 3, Plexon, Dallas, TX). In some experiments cell-attached patch-clamp recordings were made from LC neurons allowing action potential discharge to be monitored [59]. LC neurons were identified on the basis of their characteristic spontaneous firing and responses elicited by pinch stimulation applied to the contralateral hind limb [59]. The spontaneous firing rate of the LC neurons in the present study was higher than that (2-3 Hz) reported previously [50]. This is probably due to our experimental conditions for example the laminectomy and cerebellectomy may tend to increase the firing frequency. The value is similar to that of LC neurons reported by \textit{in vivo} patch-clamp recordings in a similar preparation [59].

2.6 Application of drugs

Dexmedetomidine diluted in saline was intraperitoneally injected 20 min before behavioral tests, and administered via a left femoral vein catheter during \textit{in vivo} patch-clamp and extracellular recordings. For spinal or LC application drugs were diluted in Krebs solution and superfused onto the surface of the brainstem/cord. We arbitrarily defined neurons as being sensitive to a particular drug when the frequency, amplitude or area of the synaptic responses was altered by more than 20 % of control. The actions of systemic dexmedetomidine on IPSCs were examined in SG neurons of rats aged 5-9 weeks. We tested for an effect of age on the action of dexmedetomidine by comparing results from rats of 5-6 weeks with those aged 7-9 weeks and found no difference between the groups. The drugs used were dexmedetomidine (Waterstone Technology, Carmel, IN), L-(−)- norepinephrine (+)- bitartrate salt monohydrate, clonidine, tetrodotoxin, prazosin and yohimbine (all from Sigma, St. Louis, MO).

2.7 Statistical analysis

All numerical data are shown as mean ± SEM. Statistical significance was determined as \( p < 0.05 \) using the paired Student’s \( t \)-test, one-way ANOVA with Dunnett’s post hoc test (for withdrawal threshold data), the Kruskal–Wallis test followed by the Stell-Dwass test (for sedative assessment data) or Kolmogorov-Smirnov test (cumulative distributions of IPSCs).

3. Results

3.1 Analgesic effects of systemic dexmedetomidine on mechanical nociception

We undertook a behavioral analysis to find the systemic dose range over which dexmedetomidine has analgesic effects. We used a dynamic aesthesiometer (Ugo Basile,
Italy) to evaluate the effect of dexmedetomidine (ascending doses 0.01-10 μg/kg) on mechanical withdrawal threshold. The mechanical baseline withdrawal threshold was 18.5 ± 2.0 g (n = 13). Dexmedetomidine dose-dependently increased the mechanical withdrawal thresholds at doses from 1 μg/kg (27.9 ± 2.1 g, p < 0.01; Fig. 1A). In contrast intraperitoneal injection of saline did not change the threshold (control, 20.6 ± 0.8 g; saline, 21.6 ± 0.9 g; n = 4; p > 0.05). Dexmedetomidine (1-10 μg/kg) had demonstrable analgesic actions on mechanical noxious withdrawal response at doses well below the previously reported sedative range [10; 16; 54].

3.2 Sedative effects of systemic dexmedetomidine

We performed a sedation assessment across a range of systemic dexmedetomidine doses. The sedative rating score (see section 2.4) before the administration of dexmedetomidine was 5 in all rats (n = 6). Intraperitoneal dexmedetomidine (ascending doses 0.01-30 μg/kg) dose-dependently decreased the sedation score showing statistical significance at doses from 1 μg/kg (Fig. 1B). The median sedation scores were 5 at 0.01 and 0.1 μg/kg – awake and active; 4 at 1 μg/kg – awake but inactive (p < 0.05); 3.5 at 10 μg/kg - awake but inactive to mild sedation (p < 0.01) and 2 at 30 μg/kg moderate to heavy sedation (p < 0.01). Thus a dose of 30 μg/kg of systemic dexmedetomidine was needed to produce moderate to heavy sedation - equivalent to clinical sedative levels. These results were similar to those reported for the effect of dexmedetomidine on EEG by Bol et al.[10].

3.3 Cellular mechanism of action of systemic dexmedetomidine on SG neurons

Ishii et al. showed that bath application of dexmedetomidine activated potassium conductances (EC50 of 0.62 μM) to directly inhibit SG neurons in acute spinal cord slices [31]. We therefore tested whether low dose systemic dexmedetomidine (1-10 μg/kg) elicited outward currents in SG neurons voltage clamped (Vh −70 mV) in whole cell patch clamp configuration in vivo using naive and Chung model rats. All neurons studied had membrane potentials more negative than −50 mV. The average membrane potential and the input membrane resistance were −62 ± 1.2 mV (n = 53) and 384.8 ± 28.3 MΩ (n = 53), respectively for neurons recorded with the potassium-based intracellular solution. Administration of low dose systemic dexmedetomidine did not induce any significant persistent outward currents in vivo (as would be expected to follow post-synaptic α2-adrenoceptor activation, none detectable at 1 μg/kg, n = 7; 7.0 ± 2.6 pA at 10 μg/kg, n = 7). However it was noted that higher doses of systemic dexmedetomidine (>30μg/kg) were indeed capable of inducing long lasting outward currents, 23.0 ± 6.2 pA (n = 3), (Fig. 2A, 3C). In Chung model rats, administration of dexmedetomidine (1 μg/kg) did not induce detectable outward currents in any neuron tested (n = 7).

Given the known inhibition of excitatory synaptic transmission by α2-agonists [37], we tested for an effect of systemic dexmedetomidine on spontaneous EPSCs in SG neurons. Dexmedetomidine (1-30 μg/kg) did not change the frequency (control, 23.3 ± 5.0 Hz versus Dex., 23.2 ± 5.0 Hz; p > 0.05, n = 7) or amplitude (control, 15.5 ± 3.1 pA versus Dex., 14.8 ± 2.8 pA; p > 0.05, n = 7) of spontaneous EPSCs. In the presence of tetrodotoxin (TTX), dexmedetomidine (1 μg/kg) did not change the frequency (control 6.0 ± 2.7 Hz versus +
Dex., 5.9 ± 2.7 Hz; \( p > 0.05, n = 6 \) or amplitude (control, 14.2 ± 1.9 Hz versus + Dex., 14.0 ± 1.9 Hz; \( p > 0.05, n = 6 \)) of miniature EPSCs (Fig. 2B).

Although there was no change in spontaneous and miniature EPSCs, we noted a clear and dramatic change in inhibitory synaptic transmission to SG neurons. At a holding potential of 0 mV, all SG neurons tested exhibited spontaneous IPSCs. There was a resting tone of inhibition with average frequency 48.5 ± 3.5 Hz \( (n = 69) \) and amplitude 30.9 ± 1.9 pA \( (n = 69) \). These values were similar to those reported in our previous in vivo patch clamp study [36]. Dexmedetomidine elicited a barrage of spontaneous IPSCs at doses as low as 0.1 μg/kg (shown in Fig. 3A). The enhancement of IPSCs by dexmedetomidine was detected in most SG neurons tested (19 of 21; Fig. 3A, B, C). Dexmedetomidine increased the inhibitory synaptic charge transfer (measured over a 10 second period) by 121 ± 9 % \( (n = 4) \) at 0.01 μg/kg; 134 ± 10 % \( (n = 9) \) at 0.1 μg/kg; 138 ± 5 % \( (n = 13) \) at 1 μg/kg and by 148 ± 12 % \( (n = 4) \) at 10 μg/kg compared to controls \( (316.6 ± 38.4 \text{ pC}, n = 19) \) (Fig. 3C).

Dexmedetomidine shifted the cumulative event distributions of spontaneous IPSCs to shorten the inter-event interval and increase their amplitude (Fig. 3D). Systemic administration of another \( \alpha_2 \)-agonist clonidine (40 μg/kg) produced a similar effect with increased spontaneous IPSCs (Fig. 3A, right).

### 3.4 Site of action of low dose dexmedetomidine on IPSCs

We next examined whether the enhancement of IPSCs by dexmedetomidine is mediated by a direct action at a spinal level. Dexmedetomidine (0.1-10 μM) applied by superfusion to the dorsal surface of the spinal cord [21] did not affect the spontaneous IPSCs (synaptic charge, 104.8 ± 2.4 % of control, \( n = 6, p > 0.05 \), at 0.1 μM; 97.5 ± 2.6 % of control, \( n = 7, p > 0.05 \), at 1 μM; 96.3 ± 4.9 % of control, \( n = 4, p > 0.05 \), at 10 μM) (Fig. 4A, C). In spinalised rats (cord hemisected ipsilaterally at cervical level) systemic dexmedetomidine (1 μg/kg) did not alter the spontaneous IPSCs (synaptic charge, 96.1 ± 9.4 %, \( n = 6, p > 0.05 \); Fig. 4B, C). In contrast, the direct application of noradrenaline (50 μM) to the surface of the spinal cord in spinalized rats provoked a striking barrage of IPSCs (Fig. 4B). These results suggest that low dose systemic dexmedetomidine facilitates IPSCs in SG neurons at a supraspinal level via a descending modulatory system.

### 3.5 Systemic dexmedetomidine engages the descending noradrenergic system to facilitate spontaneous IPSCs

Several previous in vitro patch-clamp studies have shown noradrenaline to facilitate spontaneous IPSCs in SG neurons in spinal cord slices – an action mediated through excitatory \( \alpha_1 \)-adrenoceptors on inhibitory interneurons [5; 6; 23; 25]. On this basis we hypothesized that systemic dexmedetomidine may be acting via the descending noradrenergic system by disinhibiting LC neurons. Direct superfusion of noradrenaline (50 μM) to the surface of the spinal cord increased spontaneous IPSCs in 40 out of 48 SG neurons tested (Fig. 5A; synaptic charge transfer increased to 219.8 ± 19.2 % of control). In 8 of 9 noradrenaline-sensitive cells, systemic dexmedetomidine (1 μg/kg) also enhanced spontaneous IPSCs (synaptic charge transfer increased to 157.2 ± 8.0 % of control). In each recorded neuron there was a strong correlation between the degree of IPSC facilitation seen with spinal noradrenaline and with systemic dexmedetomidine \( (n = 8, R^2 = 0.96; \text{Fig. 5B}) \).
Also consistent with this hypothesis was the observation that prazosin (an α₁-antagonist, 10 μM) applied to the spinal cord blocked the facilitatory action of spinal Noradrenaline on spontaneous IPSCs (n = 4; Fig. 5A). Similarly the systemic dexmedetomidine facilitation of IPSCs was significantly suppressed by concurrent spinal application of prazosin (Dex., 323.3 ± 85.4 pC versus Dex. + prazosin, 226.3 ± 50.4 pC, n = 4, p < 0.05) (Fig. 5C). Spontaneous IPSCs were weakly but not significantly decreased by spinal superfusion of prazosin (10 μM) (synaptic charge, 90.9 ± 6.1 % of control, n = 6, p > 0.05). On the other hand, the facilitatory action of systemic dexmedetomidine (1 μg/kg) on spontaneous IPSCs was not antagonized by spinal superfusion of yohimbine (4 μM), an α₂ antagonist (Fig. 5C, synaptic charge increased by Dex to 142.4 ± 9.9 % of control, n = 4, p = 0.06). The spontaneous IPSC were not affected by spinal application of yohimbine (synaptic charge, 102.5 ± 13.5 % of control, n = 4, p > 0.05).

These results suggest that the facilitatory action of systemic dexmedetomidine on spontaneous IPSCs may involve the descending noradrenergic system and spinal α₁ adrenoceptors.

### 3.6 The effect of systemically administered dexmedetomidine on LC activity

We next directly assessed whether systemic or locally applied dexmedetomidine could alter the excitability of LC neurons in vivo. Stable extracellular or cell-attached patch clamp recordings were obtained from a total of 21 LC neurons. These LC recordings showed the characteristic biphasic response to pinch stimulation applied to the contralateral hind limb (Fig. 6A) [59]. Their average spontaneous firing rates were 8.0 ± 3.1 Hz (n = 21).

During an ascending systemic dexmedetomidine dose protocol we observed that 5 out of the 7 LC neurons showed an increase (more than 20 % of control) in their firing frequency at low doses (139 ± 4 % (n = 5) at 0.01 μg/kg, 155 ± 35 % (n = 5) at 0.1 μg/kg, 200 ± 17 % (n = 5) at 1 μg/kg) which was reversed (and in some cases inhibited) at higher doses (78 ± 39 % of controls, n = 5, Fig. 6B, C; 10 - 30 μg/kg). These results indicate that systemic dexmedetomidine at lower doses activates LC neurons.

Next we applied dexmedetomidine at a concentrations of 1 nM onto the dorsal surface of the brain stem during LC recording. As shown in Fig. 6D, 4 out of 12 LC neurons showed a decrease (more than −20 % of control) in their firing rate, however 5 out of the LC neurons tested showed an increase (more than 20 % of control) in their firing rates, at 1 nM (150.9 ± 6.9 %). At 1 μM, dexmedetomidine inhibited the firing frequency in most (5 out of 6) LC neurons tested. These results suggest that dexmedetomidine at lower doses can activate some LC neurons.

### 4. Discussion

In this study, we have examined the antinociceptive action of systemic dexmedetomidine, the α₂-adrenoceptor agonist, at a spinal level in vivo. We show that inhibitory synaptic transmission within the substantia gelatinosa was dramatically enhanced by low-dose dexmedetomidine. This action was mediated through a supraspinal mechanism involving the descending noradrenergic system at doses of dexmedetomidine that produce minimal
sedation (see Fig. 7). Systemic administration of dexmedetomidine at low doses (0.01-10 μg/kg) activates the LC – a source of the descending noradrenergic projection. This activation of the descending noradrenergic pathway enhances spinal inhibitory transmission via \( \alpha_1 \)-adrenoceptors not \( \alpha_2 \)-adrenoceptors. Conversely, higher doses of dexmedetomidine (more than 10 μg/kg) strongly inhibit LC neurons (perhaps also producing the stronger sedative action) and simultaneously induces outward currents in spinal SG neurons via a direct postsynaptic \( \alpha_2 \)-activation which probably produces additional analgesic effects (see Fig. 7B).

We show that dexmedetomidine has analgesic actions on the withdrawal response to mechanical noxious stimuli (1-10 μg/kg). This compares to studies that have examined its action on thermal withdrawal latencies where it is effective at doses of 5-20 μg/kg [3; 18; 70]. Systemic dexmedetomidine produces a loss of righting reflex with an ED\(_{50}\) of ~16 μg/kg for intravenous bolus administration [54], at doses of >100 μg/kg following intraperitoneal administration [16] and sedative action on electroencephalogram at doses around 10 μg/kg [10] and a decrease in spontaneous locomotive activity at doses of >30 μg/kg [56]. Our sedative assessment showed that dexmedetomidine has detectable sedative actions at doses of 10 μg/kg and minimal sedation was detected at a dose of 1 μg/kg, but that moderate to heavy sedation was only seen at doses of 30 μg/kg. This suggests that there may be a dissociation between the dose range over which the mechanical analgesia and the clinically relevant sedative effects can be elicited by systemic dexmedetomidine. Given that mechanical analgesia was observed over lower dose range than thermal analgesia under light sedation [3; 18; 70], it raises the possibility that it may be mediated through a different cellular/molecular mechanism from those previously documented.

Based on previous in vitro studies, we hypothesized that low-dose dexmedetomidine (<10 μg/kg) would act either to directly inhibit SG neurons by activation of a potassium conductance [25; 31; 49; 58] or by presynaptic inhibition of excitatory transmission [37; 53; 58]. However, despite searching specifically for these actions, we only found outward currents at high doses (≥30 μg/kg) and never saw any effect on spontaneous excitatory synaptic transmission. A previous study demonstrated that dexmedetomidine has direct spinal effects in neuropathic pain models at intrathecal doses which are ineffective in normal rats [40]. However, we found dexmedetomidine (1 μg/kg) did not induce outward currents in SG neurons in allodynic rats. Previous behavioral and in vivo studies showed that intrathecally administered dexmedetomidine has an antinociceptive action and produced a decrease in spinal neural activity via \( \alpha_2 \)-adrenoceptors [34; 60; 69]. Such direct spinal actions to induce outward currents [31] was only seen at high doses in our study but would be expected to produce strong analgesic actions (see also Fig. 7).

Our observation of a lack of effect of dexmedetomidine on spontaneous EPSCs is consistent with previous in vitro studies showing that noradrenaline had no effect on spontaneous EPSCs recorded in SG neurons [31; 37] but was able to suppress primary afferent evoked EPSCs. To accurately elucidate the presynaptic effect of dexmedetomidine would require electrophysiological experiments to assess paired-pulse ratio and the coefficient of variation of evoked EPSCs using spinal cord slice. However, these experiments cannot currently be performed in our preparation in vivo so we aimed to test for a presynaptic effect of systemic
dexmedetomidine by recording miniature EPSCs in the presence of TTX. Systemic dexmedetomidine had no effect on miniature EPSC frequency or amplitude implying that it is not acting presynaptically to modulate excitatory transmission. Taken together these results suggested that systemic dexmedetomidine at low doses produces antinociception by a novel mechanism.

Counter to our expectations, we found low doses of systemic dexmedetomidine enhanced spontaneous IPSCs in most SG neurons (~90 %). The enhancement of spinal IPSCs by systemic dexmedetomidine was lost in spinalized animals and, importantly, was not mimicked by direct spinal application of dexmedetomidine (0.1 – 10 μM). These findings suggested that this dexmedetomidine-induced enhancement of spinal IPSCs may be dependent upon a descending pathway from the pons [28; 32; 50]. A similar IPSC facilitation by noradrenaline has been shown to be present in most (~90 %) SG neurons in spinal cord slices in vitro [5; 6] mediated by α₁-adrenoceptors. It has further been shown that α₁-adrenoceptors are expressed in the superficial dorsal horn [27; 62] and that noradrenaline acts to excite spinal GABAergic neurons via α₁-adrenoceptors [23]. We demonstrated this effect in 83% of SG neurons tested in vivo with direct spinal superfusion of noradrenaline. Almost all of the SG neurons that responded in this way to noradrenaline also showed facilitation of IPSCs by systemic dexmedetomidine. Furthermore this systemic action of dexmedetomidine on IPSCs was blocked by spinal application of the α₁-adrenoceptor antagonist prazosin, but not by the α₂-adrenoceptor antagonist yohimbine.

As we have discussed already spinal noradrenaline can exert antinociceptive actions by several mechanisms; facilitation of inhibitory synaptic responses via α₁ adrenoceptors, presynaptic inhibition of excitatory synaptic responses and hyperpolarization of SG via α₂-adrenoceptors [50; 58]. Our in vivo patch clamp recordings indicate that the facilitation of inhibitory synaptic responses occurs to alter nociceptive transmission before the other direct spinally mediated α₂-adrenoceptor actions. However the reason for this sensitivity/specificity and apparent dose threshold difference is still not known, we hope to perform more experiments to explore this interesting phenomenon.

The serotonergic pathways form another well-characterized descending monoaminergic projection to the spinal dorsal horn from the brain stem, [45; 65]. Previous patch-clamp recordings from adult spinal cord slices showed that bath-application of serotonin also facilitated inhibitory synaptic responses in SG neurons, although this serotonin-induced facilitation of IPSCs was found in a lower proportion (~50 %) of recordings [1; 64]. This suggests that both noradrenergic and serotonergic descending control systems may act through a common mechanism to regulate the tonic level of inhibition impinging upon the SG. The spinal processing of nociceptive signals is known to be held under tonic regulation by GABA/glycinergic IPSCs [57] and that the loss of such inhibition is found in chronic pain models [46]. We speculate that the regulation of inhibitory GABA/glycinergic tone may be one of the principal means by which descending monoaminergic systems regulate nociceptive transmission in the SG.

Although we show that low-dose systemic dexmedetomidine can increase the firing rate of LC neurons in vivo, as can low concentrations of dexmedetomidine applied to the dorsal
pons over the LC, this is somewhat paradoxical as it has been reported that $\alpha_2$-agonists inhibit LC neurons to exert sedative actions [2; 12; 15; 33]. In line with this finding, we noted that high doses of systemic dexmedetomidine inhibited LC activity. Interestingly a previous behavioral study also showed that injection of dexmedetomidine into the LC produced antinociception by activating a descending noradrenergic inhibitory pathway [26]; but these authors suggested that this might be mediated indirectly via the A5 noradrenergic cell group. On the basis of our findings we propose that this analgesic effect may be caused by a disinhibition of the LC by low dose dexmedetomidine leading to an increase in noradrenaline release at a spinal level. This may be via a selective presynaptic disinhibition of the LC (which is known to receive tonic inhibition). It is also worth noting that most $\alpha_2$-agonists have affinity for imidazoline receptors [29] which are highly expressed in the Nucleus Paragigantocellularis (PGi) in the ventral medulla. The LC is known to receive excitatory afferents from the PGi [17], and Pineda et al. have demonstrated that systemically administered high dose clonidine can paradoxically increase LC firing rate via an activation of imidazoline receptors. Further experiments will be needed to elucidate how LC neurons are excited by low doses of dexmedetomidine.

In conclusion, we have revealed a novel antinociceptive mechanism for systemic $\alpha_2$-adrenoceptor agonists at low doses via the facilitation of inhibitory synaptic transmission in the spinal dorsal horn. This is mediated by an activation of the descending noradrenergic inhibitory system originating from the LC in the pons which is acting to modulate inhibitory tone in the superficial dorsal horn of the spinal cord. This occurs at doses that are below the normal sedative range and by targeting this mechanism it may be possible to usefully produce analgesia with only minimal sedation, potentially extending the therapeutic utility of $\alpha_2$-agonists as analgesics. Further this potentiation of inhibitory synaptic transmission may also in part account for the known synergy between anesthetic agents that themselves potentiate inhibitory synaptic transmission (via a $\text{GABA}_A$ receptor mediated mechanism) and dexmedetomidine.

Acknowledgments

We would like to thank Dr. Kazuhiro Seki, and Ms. Hiromi Ishihara for their helpful advice on data analysis and technical support. This work was supported by grants from the programs Grants-in-Aid for Scientific Research (H. F. and K.I.) of the Ministry of Education, Science, Sports and Culture of Japan. AEP is a Welcome Trust Senior Clinical Research fellow.

References


Pain. Author manuscript; available in PMC 2014 November 20.


Figure 1. Dose-dependent anti-nociceptive and sedative action of systemic dexmedetomidine

A) Paw withdrawal thresholds to mechanical stimuli were measured in conscious animals using the Dynamic Plantar Aesthesiometer 20 min after intraperitoneal administration of dexmedetomidine (DEX, 0.01 to 10 μg/kg, n = 13). Dexmedetomidine significantly increased the withdrawal threshold at doses of 1 μg/kg (*p < 0.05) and 10 μg/kg (**p < 0.01) compared control prior to drug administration (n = 13, one-way ANOVA and Dunnett’s post hoc test).

B) Sedation rating scale 0-5. Dexametomidine significantly increased sedation at doses of 1 μg/kg (*p < 0.05) and 10 μg/kg (**p < 0.01) compared control prior to drug administration (n = 13, one-way ANOVA and Dunnett’s post hoc test).
B) The sedation rating scores were assessed 20 minutes after intraperitoneal dexmedetomidine (DEX, 0.01 to 10 μg/kg, n = 6). Median scores were significantly decreased at 1 μg/kg (*p < 0.05) and 10 μg/kg (**p < 0.01) compared with pre-administration control (Kruskal-Wallis test followed by the Stell-Dwass test) although most of the animals were considered to be still awake or only mildly sedated in this dose range. Only those animals receiving 30 μg/kg showed evidence of moderate to heavy sedation which was a significantly greater degree of sedation than that produced by either 1 or 10 μg/kg (p < 0.05).
Figure 2. Effect of systemic dexmedetomidine on SG neuron excitability

A) To look for α2-adrenoceptor mediated activation of potassium currents, we voltage clamped SG neurons (holding potential of −70mV with a potassium-based intracellular solution). The application of low doses of dexmedetomidine (1 μg/kg) did not elicit any detectable outward currents (left trace). In contrast, much higher doses of dexmedetomidine (30-75 μg/kg) were required to produce any sign of an outward current (right trace).

B) In the presence of tetrodotoxin (TTX), systemic administration of dexmedetomidine (1 μg/kg) did not enhance miniature EPSCs. The traces below are shown on an expanded time base to demonstrate the resolution of individual miniature EPSCs. The cumulative probability plots for the inter-event interval and amplitude of miniature EPSCs (from the trace in B), showing dexmedetomidine has no effect on either the frequency or amplitude ($p > 0.05$, Kolmogorov-Smirnov test).
Figure 3. Systemic dexmedetomidine dose-dependently enhances spontaneous IPSCs in the SG
A) Systemic dexmedetomidine (left trace, 0.1 μg/kg) and clonidine (right trace, 40 μg/kg) elicited barrages of spontaneous IPSCs (holding potential of 0 mV with a cesium-based based solution). The traces below are shown on an expanded time base to demonstrate the individual IPSCs.
B) Dexmedetomidine dose-dependently elicits barrages of spontaneous IPSCs.
C) Summary plot showing the enhancement of IPSCs (open circles) at dexmedetomidine doses (<10 μg/kg) that are lower than those required to induce outward currents (closed circles).

D) The cumulative probability plots for the inter-event interval and amplitude of spontaneous IPSCs (from the left trace in A). Dexmedetomidine at a dose of 0.1 μg/kg significantly increased the frequency ($p < 0.01$) and amplitude ($p < 0.01$) of spontaneous IPSCs (Kolmogorov-Smirnov test).
**Figure 4. Dexmedetomidine does not enhance IPSCs by a direct spinal action**

A) Spinal superfusion of dexmedetomidine (10 μM) had no effect on spontaneous IPSCs. In the same neuron, subsequent systemic application of dexmedetomidine (1 μg/kg) enhanced IPSCs.

B) Recordings from SG neurons in rats spinalized at the cervical level showed that systemic application of dexmedetomidine (1 μg/kg) no longer changed IPSC frequency or amplitude. However, spinal application of noradrenaline (NA, 50 μM) was able to dramatically facilitate IPSCs in the same neuron.
C) Summary showing effects of direct spinal superfusion of dexmedetomidine (0.1 – 10 μM), and systemic dexmedetomidine application in spinalized rats on normalized synaptic charge of spontaneous IPSCs.
Figure 5. Spinal noradrenaline and systemic dexmedetomidine facilitate IPSCs in the same SG neurons

A) In this neuron the facilitation of IPSCs by local superfusion of noradrenaline (NA, 50 μM, shown in upper trace) and systemic dexmedetomidine is blocked by spinal application of the α1-adrenoceptor antagonist prazosin (10 μM, lower trace). Data in A were obtained from the same neurons shown in Fig. 4A.

B) There was a strong correlation between the facilitatory actions of spinal noradrenaline and systemic dexmedetomidine on spontaneous IPSCs evoked in the same SG neurons (linear regression $R^2 = 0.96$).

C) Summary chart showing the facilitatory action of systemic dexmedetomidine on spontaneous IPSCs which is blocked in the presence of spinal prazosin (an α1 antagonist, 10 μM) but not by yohimbine (an α2 antagonist, 4 μM).
Figure 6. Activation of LC neurons by low-dose systemic dexmedetomidine

A) The characteristic biphasic response with excitation followed by inhibition of LC neuron firing by cutaneous pinch stimulation applied to the contralateral hind paw (cell-attached patch recording).

B) Extracellular recording showing several discriminated spontaneous LC units (right panels). For each cell the firing rate was increased by low dose systemic dexmedetomidine (1 μg/kg). However, higher doses of dexmedetomidine (30 μg/kg) strongly inhibited the firing of the same neurons.
C) Normalized firing rates of LC neurons after systemic dexmedetomidine (1-30 μg/kg). The firing rate was increased in 5 of 7 LC neurons at 1 μg/kg.

D) Normalized LC firing rates after superfusion of Dexmedetomidine over the floor of the 4th ventricle. Firing rates were increased in a substantial proportion of the cells (5/11) at 1nM Dexmedetomidine but the majority of the cells were inhibited by the 1μM dose.

Dashed lines in C and D show 20% increase or decrease in normalized firing frequency.
Figure 7. Schematics summarizing the proposed mechanisms of action of systemic dexmedetomidine

A) Low dose systemic dexmedetomidine (DEX) facilitates spinal IPSCs by disinhibiting a noradrenergic descending pathway. The spinal noradrenaline (NA) acts via pre- and postsynaptic $\alpha_1$ adrenoceptors on the GABAergic and glycinergic inhibitory neurons to facilitate inhibitory synaptic transmission onto SG neurons. In contrast, high dose dexmedetomidine inhibits the LC, perhaps leading to sedation, and also directly activates $\alpha_2$-adrenoceptors on the SG neurons to induce outward potassium currents that hyperpolarize and inhibit the cells producing analgesia by a different mechanism.

B) Diagram showing the multiple actions of systemically administered dexmedetomidine at different doses. The analgesia and the facilitation of spontaneous IPSCs appear with low
doses of systemic dexmedetomidine (0.1-1 μg/kg). At these doses dexmedetomidine enhanced the activity of LC neurons. Higher doses (10-75 μg/kg) of dexmedetomidine were needed to induce outward currents in SG neurons while also directly inhibiting the LC perhaps producing the known sedative effect.